Article: Low-dose colchicine effective for acute gout.(RHEUMATOLOY)

Article: Low-dose colchicine relieves gout with fewer side ...
Family Practice News;  January 1, 2009 ;     700+ words ... ... respectively). In the low-dose colchicine group, 45% had GI ... higher in the high-dose group, compared with the ... between patients on low-dose colchicine or placebo. Patients ... rates in the high-dose group (35%) and placebo ...

Article: PCI Biotech treats first dose group in phase I/II ...
Nordic Business Report;  October 19, 2009 ;     676 words ... ... BUSINESS REPORT-19 October 2009-PCI Biotech treats first dose group in phase I/II study of AmphinexA'(C)1994-2009 M2 ... announced today the completion of treatment of the first dose group in the phase I/II study of its proprietary photosensitiser ...

Article: Axonyx Announces Results of Interim Analysis of Beta- Amyloid ...
Business Wire;  March 12, 2005 ;     700+ words ... ... groups achieved statistical significance. However, there was sufficient information to conclude that enrollment to the 15mg dose group was justified, but not to the 10mg group. Completion of patient enrollment of this trial is expected in the second quarter ...

Article: Rockwell Medical Technologies, Inc. Announces Updated DSMB ...
GlobeNewswire;  April 16, 2009 ;     700+ words ... ... informed the Company that it has identified no safety concerns. The DSMB also determined there is no need to add the highest dose group of 20 ug/dl and recommended continuation of the study with the current five dose groups. Mr. Robert L. Chioini, Chairman ...

Article: Injection port features reduced recession.(Injection Port 4 from ...
McKnight's Long-Term Care News;  April 14, 2000 ;     434 words ...EPS(R) Inc., a member of the Medi-Dose(r) Group, introduces the latex-free Injection Port 4. According to the manufacturer, the device is indicated for use with catheters, extension sets and reconstruction devices. Features include reduced recession of the port, a transparent bottom to allow for

Article: Genmab to Present HuMax-CD4 Data at the Society for Investigative ...
PR Newswire;  February 18, 2004 ;     700+ words ...Genmab A/S announced today it will present data from Phase II HuMax-CD4 studies to treat cutaneous T-cell lymphoma (CTCL) at the 65th Annual Meeting of the Society for Investigative Dermatology in April. At the time the abstract was completed, 36 patients enrolled in the two ongoing HuMax-CD4

Article: New Data Presented at ACR Meeting Demonstrates Colcrys(TM) ...
PR Newswire;  October 19, 2009 ;     700+ words ... ... TM) (colchicine, USP), a low-dose colchicine, reduced the pain of gout flares ... hour period as effectively as high-dose colchicine with a side effect profile statistically ... formulation with the same efficacy of high dose colchicine while avoiding most of the toxicity ...